DanielS.ChenMDPhD

Oncology • Burlingame, CA

Melanoma

Founder and CEO, Synthetic Design Lab, Inc Founder, Engenuity Life Sciences

Join to view full profile

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile

Already have an account?

Office
Synthetic Design Lab
Burlingame, CA 94010

Summary

Cancer Immunotherapy, PD-L1, PD-1, Immunology, Drug Development, Biomarkers, Angiogenesis, Molecular Diagnostics, Biochips, Virology, Targeted Therapy, Melanoma Oncology
Specialties: Drug Development, Molecular Diagnostics, Translational Research
Medical Oncologist and Cancer Immunologist.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2000 - 2003
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1998 - 2000
Keck School of Medicine of the University of Southern CaliforniaClass of 1998
Massachusetts Institute of TechnologyBS, Biology, 1986 - 1990

Certifications & Licensure

CA State Medical License 1999 - 2024

Awards, Honors, & Recognition

https://www.pinterest.com/dschen5/dsc/

Clinical Trials

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2016 Mar 01
Terminated
Phase 1, Phase 2
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Start of enrollment: 2017 Mar 03
Active, not recruiting
Phase 2
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Start of enrollment: 2019 Sep 30
Active, not recruiting
Phase 1, Phase 2
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients Start of enrollment: 2019 May 15
Active, not recruiting
Phase 2
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) Start of enrollment: 2021 Dec 01
Recruiting
Phase 3
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis Start of enrollment: 2018 Jul 07
Completed
Phase 2
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Start of enrollment: 2020 Sep 23
Recruiting
Phase 1
Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 Start of enrollment: 2022 Jan 20
Terminated
Phase 1
Evaluation of IGM-6268 in Healthy Volunteers Start of enrollment: 2021 Dec 07
Terminated
Phase 1
Neoadjuvant Atezolizumab in Cutaneous Melanoma Start of enrollment: 2020 Sep 25
Recruiting
Phase 1
89Zr-atezolizumab PET Scan and Lobular Breast Cancer Start of enrollment: 2019 Dec 18
Terminated
Not Applicable
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer Start of enrollment: 2024 Apr 05
Recruiting
Phase 1, Phase 2
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer Start of enrollment: 2022 Apr 04
Active, not recruiting
Phase 2
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial Start of enrollment: 2024 Mar 21
Recruiting
Phase 2
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Start of enrollment: 2024 Jun 26
Not yet recruiting
Phase 1
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer Start of enrollment: 2022 Jun 14
Recruiting
Phase 3
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC Start of enrollment: 2023 Dec 07
Recruiting
Phase 2
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion Start of enrollment: 2022 Oct 22
Recruiting
Phase 2
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Start of enrollment: 2021 Aug 02
Recruiting
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT Start of enrollment: 2023 Sep 01
Not yet recruiting
Not Applicable
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2023 Aug 01
Recruiting
Phase 1
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer Start of enrollment: 2023 Jan 10
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1065 citations
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde, Daniel S. Chen
Immunity. 2020-01-14
3347 citations
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello
Lancet. 2017-01-21
3215 citations
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Nature. 2017-01-19

Journal Articles

Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L, Spira, A, Ballinger, M, Kowanetz, M, Vansteenkiste, J, Mazieres, J, Park, K, Smith, D, Artal-Cortes, A, Lewanski, C, Braiteh, F, Waterkamp, D, He, P, ..., Lancet, 1/1/2016

Abstracts/Posters

High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release
Daniel Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Too Many Trials, Not Enough PatientsNovember 18th, 2019
Drug Giant Tries New Tactic to Fight CancerMay 27th, 2019
A Cure for Cancer: How to Kill a KillerNovember 4th, 2018
Join now to see all

Committees

Co-Organizer, SITC Immuno Engineering Initiative 2022 - Present
co-organizer, SITC Deep Dive Series 2020 - Present
Board of Directors, SITC (Society of Immunotherapy for Cancer) 2018 - 2022
Co-Chair, CRI Cancer Immunotherapy Consortium 2016 - 2020
Committee Chair, Society for Immunotherapy of Cancer 2012 - 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member
American Society of Hematology - ASH
Member

Other Languages

Chinese (Mandarin)

Industry Relationships

Founder, Bionic Cell Medicines2022 - Present
Founder and CEO, Synthetic Design Lab2022 - Present
Founder, Engenuity Life Sciences2022 - Present
Chief Medical Officer, IGM Biosciences2018 - Present
Vice President, Global Head for Cancer Immunotherapy, Genentech/Roche2006 - 2018